SCHOTT Pharma AG & Co. KGaA

XTRA:1SXP Stock Report

Market Cap: €3.7b

SCHOTT Pharma KGaA Future Growth

Future criteria checks 2/6

SCHOTT Pharma KGaA is forecast to grow earnings and revenue by 15.7% and 10.4% per annum respectively. EPS is expected to grow by 15.5% per annum. Return on equity is forecast to be 18.8% in 3 years.

Key information

15.7%

Earnings growth rate

15.5%

EPS growth rate

Life Sciences earnings growth24.4%
Revenue growth rate10.4%
Future return on equity18.8%
Analyst coverage

Good

Last updated02 Jan 2025

Recent future growth updates

SCHOTT Pharma AG & Co. KGaA Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

Sep 01
SCHOTT Pharma AG & Co. KGaA Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

Earnings Miss: SCHOTT Pharma AG & Co. KGaA Missed EPS By 18% And Analysts Are Revising Their Forecasts

Jul 01
Earnings Miss: SCHOTT Pharma AG & Co. KGaA Missed EPS By 18% And Analysts Are Revising Their Forecasts

Recent updates

These 4 Measures Indicate That SCHOTT Pharma KGaA (ETR:1SXP) Is Using Debt Reasonably Well

Nov 25
These 4 Measures Indicate That SCHOTT Pharma KGaA (ETR:1SXP) Is Using Debt Reasonably Well

SCHOTT Pharma AG & Co. KGaA's (ETR:1SXP) Business Is Trailing The Market But Its Shares Aren't

Oct 27
SCHOTT Pharma AG & Co. KGaA's (ETR:1SXP) Business Is Trailing The Market But Its Shares Aren't

SCHOTT Pharma AG & Co. KGaA Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

Sep 01
SCHOTT Pharma AG & Co. KGaA Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

Is There An Opportunity With SCHOTT Pharma AG & Co. KGaA's (ETR:1SXP) 31% Undervaluation?

Aug 07
Is There An Opportunity With SCHOTT Pharma AG & Co. KGaA's (ETR:1SXP) 31% Undervaluation?

Earnings Miss: SCHOTT Pharma AG & Co. KGaA Missed EPS By 18% And Analysts Are Revising Their Forecasts

Jul 01
Earnings Miss: SCHOTT Pharma AG & Co. KGaA Missed EPS By 18% And Analysts Are Revising Their Forecasts

We Think SCHOTT Pharma KGaA (ETR:1SXP) Can Stay On Top Of Its Debt

Jun 07
We Think SCHOTT Pharma KGaA (ETR:1SXP) Can Stay On Top Of Its Debt

Calculating The Intrinsic Value Of SCHOTT Pharma AG & Co. KGaA (ETR:1SXP)

Mar 28
Calculating The Intrinsic Value Of SCHOTT Pharma AG & Co. KGaA (ETR:1SXP)

Earnings and Revenue Growth Forecasts

XTRA:1SXP - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/20271,298236852905
9/30/20261,173197772329
9/30/20251,026158522237
9/30/202495715080225N/A
6/30/202494915022191N/A
3/31/2024916135-3175N/A
12/31/202390615837220N/A
9/30/20238991526182N/A
6/30/202387314372217N/A
9/30/202282112529182N/A
9/30/202164910134132N/A
9/30/20205847719104N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1SXP's forecast earnings growth (15.7% per year) is above the savings rate (1%).

Earnings vs Market: 1SXP's earnings (15.7% per year) are forecast to grow slower than the German market (20.1% per year).

High Growth Earnings: 1SXP's earnings are forecast to grow, but not significantly.

Revenue vs Market: 1SXP's revenue (10.4% per year) is forecast to grow faster than the German market (5.6% per year).

High Growth Revenue: 1SXP's revenue (10.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 1SXP's Return on Equity is forecast to be low in 3 years time (18.8%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 03:14
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

SCHOTT Pharma AG & Co. KGaA is covered by 11 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gaurav JainBarclays
Victoria LambertBerenberg
Hugo SolvetBNP Paribas Exane